The global hormone replacement therapy (HRT) market, valued at $21 billion in 2023, is projected to grow to $38.8 billion by 2034.
Data from Transparency Market Research show the market will grow at a compound annual growth rate (CAGR) of 5.7% over this period, driven in part by increased awareness of aging-related health issues.
HRT is used to alleviate symptoms associated with menopause, andropause, and other hormonal imbalances. It can also prevent long-term health issues such as osteoporosis and cardiovascular diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze